Download alert25-bmj-2006_333_1145

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
Document related concepts
no text concepts found
Transcript 
Schematic of the state transition model
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Observed and predicted difference in annual rates
of MACE or deaths from vascular causes between
groups allocated to placebo and simvastatin
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Predicted life years gained (95% confidence interval)
by full compliance with lifetime use of 40 mg
simvastatin daily for the population of the HPS (not
discounted)
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Outcome measures with full compliance with lifetime use
of generic 40 mg simvastatin daily for the HPS population
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Additional scenarios of full compliance with 40 mg
simvastatin daily within the population of the HPS
Values are life years gained
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Cost (£) per life year gained (unless stated otherwise)
for various scenarios of full compliance with 40 mg
simvastatin daily for the population of the HPS
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Life years gained by full compliance with lifetime use of
generic 40 mg simvastatin daily projected beyond the
population of the HPS
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Cost effectiveness of full compliance with lifetime use of
generic 40 mg simvastatin daily projected beyond the
population of the HPS
Heart Protection Study Collaborative Group BMJ; 2006;333:1145-
Related documents